Research
Hormonal
Insulin resistance drives NAFLD pathogenesis through two main mechanisms: increased adipose tissue lipolysis (free fatty acid overflow) and increased hepatic de novo lipogenesis (fatty acid synthesis), leading to triglyceride accumulation.
Addressing insulin resistance is the most critical step in managing fatty liver. This involves caloric restriction, weight loss, and dietary changes that reduce insulin spikes, thereby reducing both the release of fatty acids from fat tissue and the liver's production of new fat.
StrongSupportsVERY_HIGH confidence
In an insulin resistant setting, insulin is unable to inhibit lipolysis in adipose tissue leading to overflow of free FA into the bloodstream and in the liver. In the liver, hyperinsulinemia and hyperglycemia induce the synthesis of fatty acid and cholesterol which results in increased triglyceride synthesis and VLDL assembly and secretion.
Why this rating
This is a foundational concept in the paper, supported by extensive literature review and multiple animal/human studies.
Source
Nonalcoholic Fatty Liver Disease: Focus on Lipoprotein and Lipid Deregulation
Klementina Fon Tacer et al. · Journal of Lipids · 2011
DOI 10.1155/2011/783976
narrative_reviewCited 232×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- In the context of Nonalcoholic Fatty Liver Disease (NAFLD), hepatic triglyceride accumulation acts as a hepatoprotective buffering mechanism against lipotoxicity; inhibiting triglyceride synthesis (e.g., via DGAT2 inhibition) exacerbates liver damage and fibrosis despite reducing steatosis.Good
- Dietary cholesterol is a distinct and critical risk factor for the progression of NAFLD to NASH, driving inflammation and oxidative stress independently of total lipid accumulation.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →